Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was reported at $1.08 billion, reflecting a year-over-year growth of approximately 2% excluding China, and was above the guidance range [6][18] - Non-GAAP operating margin expanded by 190 basis points to 24.5%, and non-GAAP diluted EPS increased to $1.34, representing an 18% year-over-year growth [18][24] - Greater China revenue was $52 million, with overall revenue growth outside of China being a significant milestone [18][25] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $747 million, roughly flat year-over-year, but up about 3% excluding China [18][22] - Clinical business saw double-digit revenue growth outside of China, driven by comprehensive genomic profiling and sequencing-intensive applications [18][22] - Research consumable sales declined by high single digits outside of China due to funding uncertainty and pricing dynamics [18][22] Market Data and Key Metrics Changes - The transition to the NovaSeq X platform progressed significantly, with approximately 78% of volumes and 51% of revenue in Q3 being sequenced on X [19][20] - Total sequencing GB output on connected high and mid-throughput instruments grew at a rate of more than 30% year-over-year, primarily driven by clinical demand [21] - The instruments business in Greater China experienced a decline of approximately 54% due to export restrictions [22] Company Strategy and Development Direction - The company is focusing on three strategic pillars: growing the core sequencing business, scaling into multi-omics, and expanding services, data, and software capabilities [9][12] - The launch of Illumina Protein Prep and the five-base solution are part of the strategy to enhance multi-omics capabilities [11][12] - The company aims to achieve high single-digit revenue growth and 20% non-GAAP operating margins by 2027, excluding Greater China [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical business as the primary driver of revenue growth, with expectations for a gradual return to growth in the research segment [15][16] - The company remains cautious about the regulatory environment in China but is encouraged by the resilience shown in that market [31] - Management highlighted the importance of customer feedback in shaping future product offerings and maintaining competitive advantage [14][45] Other Important Information - The company has increased its revenue guidance for Greater China by $20 million to approximately $220 million for the year [25] - Non-GAAP operating margin guidance has been raised by approximately 60 basis points to a range of 22.75% to 23% [26] - The company ended the quarter with approximately $1.28 billion in cash and cash equivalents, with plans for continued share repurchases [24] Q&A Session Summary Question: Insights on China and 2026 outlook - Management is pleased with performance in China despite unresolved regulatory issues and is optimistic about customer relationships [30][31] Question: 2026 revenue growth framework - Management acknowledges the potential for low single-digit revenue growth in 2026, driven by clinical growth and muted research revenue [32][34] Question: Margin outlook and operational efficiency - Management is confident in further margin expansion due to disciplined cost management and operational improvements [33][35] Question: Consumables growth and market dynamics - The growth in consumables was primarily driven by clinical demand, with no significant pull forward from academic or government segments [37][38] Question: Competitive landscape and market pressures - Management views competition positively, emphasizing Illumina's multi-dimensional value proposition over single-dimensional competition [44][45] Question: Future instrument placements and market trends - Management expects stable instrument placements moving forward, supported by ongoing demand in clinical and research applications [46][47] Question: Research market dynamics and funding predictability - Management notes that predictability in grant funding is crucial for research spending, with ongoing monitoring of the funding environment [60]

Core Insights - Illumina has established a new business unit called BioInsight, focusing on large project contracting, data sharing platforms, and the development of multi-omics AI tools to enhance sequencing business integration and intelligence upgrades [1][2] Group 1: New Business Unit - The new business unit BioInsight will be divided into three main areas: national large project contracting, building a data sharing platform, and developing AI tools for strategic partners and multi-omics analysis [1] - Rami Mehio, previously the global software and IT head at Edico Genome, has been appointed as the General Manager of BioInsight [2] Group 2: Market Challenges - Illumina faces significant challenges globally, including technological competition from emerging sequencing companies, a highly competitive market environment, poor financial performance, and management instability [2] - In the Chinese market, Illumina's challenges are particularly pronounced, having been placed on the "unreliable entity list" in February 2025, which has closed export channels for core equipment to China [2] - In 2024, Illumina's revenue in the Greater China region declined by 16% year-on-year, with market share dropping from 59% in 2020 to approximately 12.36% in the first three quarters of 2024, leading many commercial users to switch to domestic sequencing instruments [2]

Growth Drivers - ARKInvest 认为上个世纪电力和引擎将 GDP 增长率从 0.5% 提升至 3% [1] - ARKInvest 预测 AI、机器人、储能、区块链和多组学将推动 GDP 增长至 7% [1]